Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

CAR-T & Cellular Therapy

The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT

The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory…

Date: 15th March 2024

Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy

Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding…

Date: 29th February 2024

Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks

The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells…

Date: 22nd February 2024

Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets

The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic…

Date: 18th January 2024

iwNHL 2023 Session V: Expanding the CAR platform in NHL

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as…

Date: 15th December 2023

iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials

The biennial International Workshop on Chronic Lymphocytic LeukemiaTM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who…

Date: 7th December 2023

Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP

In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in…

Date: 24th November 2023

iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as…

Date: 3rd November 2023

Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL

The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent…

Date: 23rd August 2023

Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma

Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory…

Date: 3rd August 2023

Overcoming barriers to CAR-T therapy: improving access and cost

CAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies, providing hope to several individuals…

Date: 27th July 2023

Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team

Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage….

Date: 11th July 2023